Literature DB >> 11069724

Modification of articular cartilage and subchondral bone pathology in an ovine meniscectomy model of osteoarthritis by avocado and soya unsaponifiables (ASU).

M A Cake1, R A Read, B Guillou, P Ghosh.   

Abstract

OBJECTIVE: To examine the effect of an oral preparation of avocado and soya unsaponifiables (ASU) on the development of joint pathology in an ovine model of osteoarthritis (OA), using computer-assisted histomorphometric methods.
DESIGN: OA was induced in ovine knee joints by bilateral lateral meniscectomy (N=32). ASU (900 mg/weekday) was given orally to half the group (MenX+ASU), the remainder receiving placebo (MenX). Sixteen animals were used as non-operated controls (NOC). At 3 and 6 months post-meniscectomy, histological sections from the medial and lateral femoral condyles (MFC, LFC), tibial plateaux (MTP, LTP) and trochlear groove (TG) were prepared from all joints. Sections were scored using traditional histopathological scales, and computerized image analysis, measuring total cartilage area, uncalcified cartilage (UCC) and subchondral bone plate (SCP) thickness, and intensity of articular cartilage toluidine blue staining (mean greyscale intensity, black=255) as an index of proteoglycan (PG) content.
RESULTS: Computerized image analysis showed significant histological differences not detectable by traditional scoring methods. ASU-treated animals at 6 months showed reduced loss of toluidine blue stain in the MTP (P=0.015) and LTP (P=0.001), and significantly greater staining in the TG than either placebo or NOC groups (P=0.011). UCC thickness increased after meniscectomy, but tended to be highest in ASU-treated animals, significantly so in the middle zone of the LFC (MenX+ASU: 1.03+/-0.21mm vs MenX: 0.79+/-0.14 mm, P=0.018; NOC: 0.77+/-0.17 mm). Lateral compartment SCP thickness increased post-meniscectomy but was increased significantly less in the inner zone of the LTP in ASU-treated sheep (MenX+ASU: 1.37+/-0. 23 mm vs MenX: 1.68+/-0.28 mm, P=0.033; NOC=1.22+/-0.33 mm).
CONCLUSIONS: In this model ASU treatment following meniscectomy appeared to confer a subtle but statistically significant protective effect on articular cartilage. Although the drug failed to prevent focal cartilage lesions, characteristic of this model, histomorphometric analysis demonstrated greater PG content and UCC thickness in adjacent joint regions of ASU-treated animals. In addition, a statistically significant reduction of subchondral bone sclerosis was noted in the LTP region of the drug-treated group. An anabolic effect on chondrocytes, resulting in the stimulation of matrix production in regions distant to the insult, was also suggested by the data. These findings support other studies which have proposed that ASU may exhibit disease-modifying anti-OA activity. Copyright 2000 OsteoArthritis Research Society International.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11069724     DOI: 10.1053/joca.1999.0315

Source DB:  PubMed          Journal:  Osteoarthritis Cartilage        ISSN: 1063-4584            Impact factor:   6.576


  18 in total

1.  Stereologic analysis of tibial-plateau cartilage and femoral cancellous bone in guinea pigs with spontaneous osteoarthritis.

Authors:  Susanne X Wang; Larry Arsenault; Ernst B Hunziker
Journal:  Clin Orthop Relat Res       Date:  2011-10       Impact factor: 4.176

2.  Comparative spatial and temporal localisation of perlecan, aggrecan and type I, II and IV collagen in the ovine meniscus: an ageing study.

Authors:  James Melrose; Susan Smith; Martin Cake; Richard Read; John Whitelock
Journal:  Histochem Cell Biol       Date:  2005-10-28       Impact factor: 4.304

Review 3.  Targeting subchondral bone for treating osteoarthritis: what is the evidence?

Authors:  Steeve Kwan Tat; Daniel Lajeunesse; Jean-Pierre Pelletier; Johanne Martel-Pelletier
Journal:  Best Pract Res Clin Rheumatol       Date:  2010-02       Impact factor: 4.098

4.  The influence of scaffold material on chondrocytes under inflammatory conditions.

Authors:  Heenam Kwon; Lin Sun; Dana M Cairns; Roshni S Rainbow; Rucsanda C Preda; David L Kaplan; Li Zeng
Journal:  Acta Biomater       Date:  2013-01-16       Impact factor: 8.947

Review 5.  Osteoarthritis and nutrition. From nutraceuticals to functional foods: a systematic review of the scientific evidence.

Authors:  Laurent G Ameye; Winnie S S Chee
Journal:  Arthritis Res Ther       Date:  2006       Impact factor: 5.156

6.  Management of Osteoarthritis with Avocado/Soybean Unsaponifiables.

Authors:  Blaine A Christiansen; Simi Bhatti; Ramin Goudarzi; Shahin Emami
Journal:  Cartilage       Date:  2015-01       Impact factor: 4.634

7.  Protective effects of total fraction of avocado/soybean unsaponifiables on the structural changes in experimental dog osteoarthritis: inhibition of nitric oxide synthase and matrix metalloproteinase-13.

Authors:  Christelle Boileau; Johanne Martel-Pelletier; Judith Caron; Philippe Msika; Georges B Guillou; Caroline Baudouin; Jean-Pierre Pelletier
Journal:  Arthritis Res Ther       Date:  2009-03-16       Impact factor: 5.156

8.  Significant synovial pathology in a meniscectomy model of osteoarthritis: modification by intra-articular hyaluronan therapy.

Authors:  M M Smith; M A Cake; P Ghosh; A Schiavinato; R A Read; C B Little
Journal:  Rheumatology (Oxford)       Date:  2008-06-19       Impact factor: 7.580

9.  Metabolic effects of avocado/soy unsaponifiables on articular chondrocytes.

Authors:  Louis Lippiello; Joseph V Nardo; Robert Harlan; Tiffany Chiou
Journal:  Evid Based Complement Alternat Med       Date:  2008-06       Impact factor: 2.629

10.  Randomised, controlled trial of avocado-soybean unsaponifiable (Piascledine) effect on structure modification in hip osteoarthritis: the ERADIAS study.

Authors:  Emmanuel Maheu; Christian Cadet; Marc Marty; Dominique Moyse; Isabelle Kerloch; Philippe Coste; Maxime Dougados; Bernard Mazières; Tim D Spector; Hafid Halhol; Jean-Marie Grouin; Michel Lequesne
Journal:  Ann Rheum Dis       Date:  2013-01-23       Impact factor: 19.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.